trending Market Intelligence /marketintelligence/en/news-insights/trending/7_PEWkyqo_ulARJbEt4Ufw2 content esgSubNav
In This List

Strides Shasun receives US FDA approval for Parkinson's disease treatment

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Strides Shasun receives US FDA approval for Parkinson's disease treatment

Strides Shasun Ltd. said the U.S. Food and Drug Administration approved its amantadine hydrochloride capsules USP, 100 milligrams.

The drug, which the company will launch immediately, is used as treatment for Parkinson's disease and as pain reliever in the treatment of shingles.

The U.S. market for the product is about $25 million with three generic players, Strides Shasun said in a news release, citing IMS data.